You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An optimized NK2R agonist for 'on-demand' voiding

    SBC: Dignify Therapeutics LLC            Topic: NIA

    PROJECT SUMMARY Underactive bladderUABis a clinically important problem in the elderlyUAB is characterized by weak bladder contractions and incomplete bladder emptying that result in symptoms of voiding frequencynocturiaand incontinenceand it can lead to serious complications such as permanent bladder and kidney damageAging related UAB may affect almostof Americans overand nearly two thirds of inc ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Humanized Kidney Cellular Toxicity Platforms

    SBC: DISCOVERYBIOMED, INC.            Topic: NIEHS

    Principal Investigators for Small Business DiscoveryBioMed Inc DBM Project Summary Abstract The over arching goal of this proposed SBIR driven program is to create relevant DiscoveryBioMed DBM human cellular toxicity HCT platforms for the kidney grown in D and in D cell culture formats for a new gold standard in lead therapeutic asset and materials in vitro testing and to reduce marke ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Safety and Efficacy of a Titratable External Shunt

    SBC: CAMRAS VISION, INC.            Topic: W

    Glaucoma is a diverse group of chronic diseases that causes irreversible damage to the optic nerve and is a leading cause of blindness affectingmillion people worldwideIt is estimated thatinpeople who receivepropertreatment for glaucoma still experience loss of visionThe only proven method of treating glaucoma is to reduce the pressure in the eyeIntraocular PressureIOPAdvanced glaucoma must achiev ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. SWIFT ActiveScreener research and development of an intelligent web based document screening system

    SBC: Sciome LLC            Topic: NIEHS

    Project Summary More than systematic reviews are performed each year in the fields of environmental health and evidence based medicine with each review requiring on average between six months to one year of effort to complete In order to remain accurate systematic reviews require regular updates after their initial publication with most reviews out of date within five years In the sc ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Novel Targeted Chemotherapeutics for the Treatment ofMalignant Pleural Mesothelioma

    SBC: FLAG THERAPEUTICS INC            Topic: 102

    Abstract Malignant Pleural MesotheliomaMPMis an aggressive cancer effecting the lining of the lungs and is most often caused by exposure to asbestosMPM is difficult to detect and is typically diagnosed late resulting in a median survival of just one year and ayear median survival of onlyPemetrexedPmxis the standard of care but quality of life is poor due to Pmx toxicitiesThe purpose of this Direct ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Oral formulation for novel inhibitor of Ras driven cancers

    SBC: ADT Pharmaceuticals, LLC            Topic: NCI

    Mutations in the ras family of genes were first identified in human cancer overyears agoSuch mutations may result in the constitutive activation of one or more of three major Ras protein isoformsincluding H RasNRasor K Rasthat mediate important signaling pathways leading to uncontrolled cell growth and tumor developmentActivating mutations of ras genes occur de novo in approximately one third of a ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma Device development and First in Human clinical trial

    SBC: Focal Medical, Inc.            Topic: 102

    PROJECT SUMMARY Advanced Chemotherapy Technologies ACT has developed a proprietary implantable iontophoretic device that facilitates the infusion of chemotherapy agents directly into a cancer tumor minimizing toxic exposure to the vascular system and other organs ACT is focusing specifically on treating pancreatic cancer with gemcitabine for this proposal Pancreatic cancer has a five year sur ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Multi Scale In Vitro D Tissue Model of Vascularized Bone Cartilage Interactions

    SBC: CFD RESEARCH CORPORATION            Topic: NIAMS

    Abstract Current in vitro models of vascularized bone tissues do not mimic the in vivo microenvironment comprising of diverse cell types in communication with each other through stromal barriers In addition they are hampered by lack of real time visualization and quantitation of vasculature bone as well as bone cartilage interactions In contrast animal models while providing useful information ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Nanodrug Delivery System to Optimize Dose of Oncology Drugs

    SBC: MAA Laboratories Inc.            Topic: 102

    PROJECT SUMMARY It is estimated thatof anti cancer small molecules and up toof late stage investigational compounds are poorly soluble in waterand such compounds are often associated with significant clinical problemssuch as inconsistent dosing and variable pharmacokineticsPKDasatinib is an orally bioavailable tyrosine kinase inhibitorTKIindicated for the treatment of chronic myelogenous leukemiaC ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Standardization of a Fluidic In Vitro Exposure System for IVIVE Predictive Toxicity Data

    SBC: SCIKON INNOVATION, INC.            Topic: 300

    Project Summary The high failure rate of drugs late in clinical development is an indication that nonclinical in vitro models and animal models are not accurately predicting compound performance in humansOnlyout ofmolecules identified by pharmaceutical companies as a potential drug candidate is successfully advanced through FDA approvalDrug toxicity in general and drug induced liver injuryDILIin p ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government